Latest Breaking News On - Cue biopharma inc - Page 5 : comparemela.com

Cue Biopharma, Inc (NASDAQ:CUE) Sees Significant Growth in Short Interest

Cue Biopharma, Inc. (NASDAQ:CUE – Get Free Report) saw a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 3,650,000 shares, a growth of 6.7% from the December 31st total of 3,420,000 shares. Based on an average daily volume of 361,500 shares, the short-interest ratio […]

United statesPiper sandlerAmerican international group incCue biopharma incSanders morris harrisSilverarc capital managementVirtu financialBarclays plcCue biopharmaGet free reportInternational groupMorris harrisCapital managementCue biopharma dailyNasdaq cue

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesMarie campinellDaniel passeriMaya romanchuckLifesci communicationsCue biopharma incCorporate communicationsOncology summitCue biopharmaSelective targeting

Cue Biopharma To Present At The JMP Securities Hematology And Oncology Summit

Cue Biopharma To Present At The JMP Securities Hematology And Oncology Summit
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesDaniel passeriMarie campinellCorporate communicationsCue biopharma incOncology summitCue biopharmaSelective targeting

Cue Biopharma, Inc (NASDAQ:CUE) Q3 2023 Earnings Call Transcript

Operator: Good afternoon, ladies and gentlemen, and welcome to the Cue Biopharma Third Quarter 2023 Earnings Call. At this time, all lines are in listen-only mode.

Dan passeriMatteo levisettiStephen willeyDaniel passeriKerri ann millarReni benjaminRichard dipaolo at saint louis universityFree accounting softwareWashington universityCue biopharma incCue biopharmaCall transcript novemberCue biopharma third quarterChief executiveManish suriChief scientific officer

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms Tumor 1 Positive Cancers at SITC 2023 -November 03, 2023 at 12:01 pm EDT

Overall response rate of 47% and disease control rate of 65% in first line recurrent/metastatic HNSCC patients treated with CUE-101 and KEYTRUDA® ORR of 56% in patients with low expression of.

United statesSan diegoDan passeriMatteo levisettiJennifer eva selfridgeMaya romanchukChristine chungMarie campinellLifesci communicationsSociety for immunotherapy of cancerMoffitt cancer centerCue biopharma incUniversity hospitals cleveland medical centerCorporate communicationsDepartment of headH lee moffitt cancer center